Drug reference
tiludronate
Bisphosphonate · Antiresorptive agent
BisphosphonateAntiresorptive agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Not yet extracted
Indications
Paget disease
Dosing
- Adult
- 400 mg/day orally for 3 months.
Pharmacokinetics
Bioavailability
6%
Contraindications
- creatinine clearance <35 mL/min
Side effects
Common
heartburnesophageal irritationesophagitisabdominal paindiarrhea
Serious
- osteonecrosis of the jaw
- esophageal ulcers
- esophageal erosions
Related guidelines
Other Bisphosphonate drugs
Ask House about tiludronate
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: Goodman & Gilman 14e·Updated: 2026-05-10